You have 9 free searches left this month | for more free features.

Inhibitor

Showing 1 - 25 of >10,000

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Metastatic Colorectal Cancer Trial (LB-100, Azenosertib)

Not yet recruiting
  • Metastatic Colorectal Cancer
  • (no location specified)
Oct 31, 2023

Metastatic Microsatellite-stable Colorectal Cancer Trial (LB-100, Atezolizumab)

Not yet recruiting
  • Metastatic Microsatellite-stable Colorectal Cancer
  • (no location specified)
Sep 1, 2023

Compare Overall Survival in Medicare Metastatic Breast Cancer

Active, not recruiting
  • Breast Cancer
  • New York, New York
    Pfizer New York
Oct 11, 2023

Hemodialysis Access Failure Trial in Shanghai (pcsk9 inhibitor)

Recruiting
  • Hemodialysis Access Failure
  • pcsk9 inhibitor
  • Shanghai, Pudong, China
    Yuanyuan Xie
Sep 10, 2023

Gastrointestinal Tumor Trial in Hangzhou (Water-filtered infrared A radiation whole-body hyperthermia (HECKEL 3000MT-4T,

Completed
  • Gastrointestinal Tumor
  • Water-filtered infrared A radiation whole-body hyperthermia (HECKEL 3000MT-4T, Germany)
  • tislelizumab (BeiGene, China) combined with PD-1 inhibitor
  • Hangzhou, China
    Zhejiang Hospital
Sep 1, 2023

Nasopharyngeal Carcinoma Trial in Shanghai (Anti-EGFR and PD-1 inhibitor arm)

Recruiting
  • Nasopharyngeal Carcinoma
  • Anti-EGFR and PD-1 inhibitor arm
  • Shanghai, Shanghai, China
    Eye & ENT Hospital of Fudan University
Nov 26, 2023

Breast Cancer Metastatic Cancer Trial in Shanghai (Fluzoparib, Dalpiciclib, Fulvestrant/AI)

Recruiting
  • Breast Cancer Metastatic Cancer
  • Shanghai, Shanghai, China
    Breast cancer institute of Fudan University Cancer Hospital
Feb 26, 2023

Breast Cancer Trial in Guangzhou (Capecitabine, Aromatase Inhibitor)

Active, not recruiting
  • Breast Cancer
  • Guangzhou, Guangdong, China
    State Key Laboratory of Oncology in South China, Sun Yat-sen Uni
Jan 27, 2023

Breast Cancer, Breast Tumor, Breast Cancer Stage IV Trial in San Juan (MBQ-167)

Recruiting
  • Breast Cancer
  • +2 more
  • San Juan, Puerto Rico
    FDI Clinical Research
Oct 4, 2023

Melanoma Trial in Toulouse (Nivolumab+Ipilimumab in combination with Anti TNF-a Certolizumab, Nivolumab+Ipilimumab in

Active, not recruiting
  • Melanoma
  • Nivolumab+Ipilimumab in combination with Anti TNF-α Certolizumab
  • Nivolumab+Ipilimumab in combination with Anti TNF-α Infliximab
  • Toulouse, France
    Institut Claudius Regaud IUCT-ONCOPOLE
Nov 18, 2022

Pancreatic Ductal Adenocarcinoma Trial (combination therapy with no MEKi, combination therapy with MEKi-HCQ, combination therapy

Not yet recruiting
  • Pancreatic Ductal Adenocarcinoma
  • combination therapy with no MEKi
  • +3 more
  • (no location specified)
Nov 29, 2022

Nasopharyngeal Carcinoma Trial in Guangzhou (Dalpiciclib Isetionate Tablets, Camrelizumab)

Recruiting
  • Nasopharyngeal Carcinoma
  • Dalpiciclib Isetionate Tablets, Camrelizumab
  • Guangzhou, Guangdong, China
    Department of Nasopharyngeal Carcinoma, Sun Yat-sen University C
Feb 2, 2023

ARNI and ACE Inhibitor/ARB Medication in Patient With HFrEF

Recruiting
  • Heart Failure
  • Mortality
  • Angiotensin receptor neprilysin inhibitor (ARNI)
  • Renin-Angiotensin System Inhibitor (RAS inhibitor)
  • Wonju, Gangwondo, Korea, Republic of
    Yonsei University Wonju College of Medicine
Dec 20, 2022

Ketoses, Metabolic Trial (SGLT2 inhibitor + low-carb diet, + low-carb diet)

Not yet recruiting
  • Ketoses, Metabolic
  • SGLT2 inhibitor + low-carb diet
  • placebo + low-carb diet
  • (no location specified)
Dec 28, 2022

Diabetes, Cellular Senescence, Sodium-Glucose Transporter 2 Inhibitors Trial in Seoul (SGLT2 inhibitor, Glimepiride)

Not yet recruiting
  • Diabetes Mellitus
  • +2 more
  • Seoul, Korea, Republic of
    Yonsei University College of Medicine
Aug 1, 2023

Alcohol Use Disorder Trial in Catonsville (Diclofenac, Placebo)

Not yet recruiting
  • Alcohol Use Disorder
  • Catonsville, Maryland
    Maryland Psychiatric Research Center (MPRC) Treatment Research P
Aug 31, 2023

Nasopharyngeal Carcinoma, Immune Checkpoint Inhibitor, Radiotherapy Trial (radiation, drug, biological)

Not yet recruiting
  • Nasopharyngeal Carcinoma
  • +3 more
  • Intensity Modulated Radiation Therapy
  • +3 more
  • (no location specified)
Jul 11, 2023

Melanoma (Skin), Skin Cancer, Skin Melanoma Trial in Tampa (Vemurafenib, Cobimetinib)

Recruiting
  • Melanoma (Skin)
  • +3 more
  • Tampa, Florida
    H. Lee Moffitt Cancer Center and Research Institute
Dec 30, 2022

Anemia in Dialysis-dependent CKD Patients Trial in Alexandria (Roxadustat)

Recruiting
  • Anemia in Dialysis-dependent CKD Patients
  • Alexandria, Egypt
    Alexandria University
Oct 29, 2023

NSCLC (NSCLC) Trial (Alirocumab and Cemiplimab)

Not yet recruiting
  • Non-small Cell Lung Cancer (NSCLC)
  • Alirocumab and Cemiplimab
  • (no location specified)
Jan 31, 2023

Breast Cancer, Aromatase Inhibitor Associated Musculoskeletal Symptoms (AIMSS), Joint Pain Trial in Los Angeles, Torrance (Tart

Not yet recruiting
  • Breast Cancer
  • +2 more
  • Tart Cherry
  • Omega 3 FA (Fish Oil)
  • Los Angeles, California
  • +1 more
Nov 7, 2023

Adenocarcinoma Esophagus, Locally Advanced Adenocarcinoma, Siewert Type I Adenocarcinoma of Esophagogastric Junction Trial

Not yet recruiting
  • Adenocarcinoma Esophagus
  • +3 more
  • (no location specified)
Sep 13, 2023

Chemo-Induced Thrombocytopenia Trial (Hetrombopag)

Not yet recruiting
  • Chemotherapy-Induced Thrombocytopenia
  • (no location specified)
Jul 24, 2023

Immune Checkpoint Inhibitor-related Cardiotoxicity

Not yet recruiting
  • Immune Checkpoint Inhibitors, Cardiotoxicity
  • Cardiac magnetic resonance
  • (no location specified)
Nov 10, 2023

Breast Cancer Trial in Marseille (M1774, Fulvestrant injection)

Not yet recruiting
  • Breast Cancer
  • Marseille, France
    Institut Paoli Calmettes
Aug 9, 2023